Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

Abstract

Even under the stringent criteria for using adalimumab, the response rate was comparable to those without stringent criteria.